3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Genitourinary
2
Conditions
Prostatic Neoplasms
1619
Carcinoma, Renal Cell
499
Urinary Bladder Neoplasms
459
Carcinoma, Transitional Cell
233
Breast Neoplasms
225
Kidney Neoplasms
215
Neoplasms
191
Carcinoma, Non-Small-Cell Lung
173
Colorectal Neoplasms
168
Ovarian Neoplasms
161
Melanoma
161
Neoplasm Metastasis
142
Lung Neoplasms
127
Non-Muscle Invasive Bladder Neoplasms
107
Pancreatic Neoplasms
101
Stomach Neoplasms
99
Uterine Cervical Neoplasms
91
Squamous Cell Carcinoma of Head and Neck
86
Endometrial Neoplasms
82
Carcinoma, Hepatocellular
76
Sarcoma
75
Esophageal Neoplasms
71
Head and Neck Neoplasms
68
Adenocarcinoma
67
Triple Negative Breast Neoplasms
65
Colonic Neoplasms
53
Testicular Neoplasms
52
Disease
47
Wilms Tumor
46
Urologic Neoplasms
45
Interventions
darolutamide
2
enzalutamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Biochemically Recurrent Prostate Cancer
×
Genitourinary
×
1 year
×
Clear all
NCT05794906
2026-05-19
ARASTEP
Bayer
Phase 3
Active not recruiting
985 enrolled
NCT05526248
2026-03-11
ARAMON
Bayer
Phase 2
Completed
28 enrolled
14 charts